
Fueling our pipeline with innovation
Our definition of innovation goes beyond mere drug development
Our R&D pipeline is a source of great excitement; indeed we currently have several new drug candidates in different phases of development, all of which are being actively managed to ensure a continuous flow of innovation with the potential to improve patient outcomes.
“Grünenthal is committed to deliver significant therapeutic advances to serve patients in need. In addition our highly valued collaborative spirit is building an enriched understanding of the underlying mechanisms driving pain that will allow us to discover and produce the medicines of the future.”
- driving our innovative projects via a broad networked approach
- enriching our pipeline with external innovation projects and advancing these important collaborations
- complementing our own capabilities with the extensive external knowledge and expertise to deliver real benefits.
Our projects in brief
New Chemical Entities
| Research | Early Development | Phase I | Phase II | Phase III | Submission/ Approval |
|---|---|---|---|---|---|
Program 1: Painful Inflammatory Diseases
Global
|
Candidate 1 Pain; Symptomatic Approach
Global
|
Cebranopadol
Global
|
Neridronate (BTD/ Breakthrough Designation , FTD/ Fast Track Designation)
Global
|
Tapentadol Pediatric Program Acute
Global
|
|
Program 2: Pain; Disease Modifying Potential
Global
|
Candidate 2 Painful Inflammatory Diseases
Global
|
NOP (Nociceptin Receptor) agonist for local administration (indication 1)
Global
|
Tapentadol Pediatric Program Chronic
Global
|
Lesinurad + Allopurinol Fixed Dose Combination
Global
|
|
Program 3: Pain; Disease Modifying Potential
Global
|
Candidate 3 Pain; Symptomatic Approach
Global
|
NeoSTX FDC
Global
|
Qutenza sNDA for DPN
Global
|
||
Program 4: Pain; Disease Modifying Potential
Global
|
Candidate 4 Painful Inflammatory Diseases
Global
|
||||
Program 5: Pain; Symptomatic Approach
Global
|
|||||
Program 6: Pain; Disease Modifying Potential
Global
|
|||||
Program 7: Pain; Symptomatic Approach
Global
|
|||||
Program 8: Pain; Disease Modifying Potential
Global
|
|||||
Program 9: Pain; Disease Modifying Potential
Global
|
|||||
Program 10: Pain; Disease Modifying Potential
Global
|
Medical Devices
- Global
- Valid As Of 6/4/2019
-
- Filter
| Technical/Preclinical Development | Clinical Testing | Submission/ Approval |
|---|---|---|
|
Abuse Deterrent Formulations
Devices and Technology Platforms (3)
Global
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 1
Global
|
Surgical Sealants
Cutis EU (Adhesys Medical)
Global
|
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 5
Global
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 2
Global
|
|
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 6
Global
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 3
Global
|
|
|
Abuse Deterrent Formulations
Ondosis + Abuse Deterrent Formulation Project 7
Global
|
Abuse Deterrent Formulations
Abuse Deterrent Formulation Project 4
Global
|
|
|
Surgical Sealants
Cutis US (Adhesys Medical)
Global
|
||
|
Surgical Sealants
Vivo (Adhesys Medical) (Expedited Access Pathway)
Global
|
||
|
Digital Health
Digital Health Project 1
Global
|
||
|
Digital Health
Digital Health Project 2
Global
|